...
lxrx-img

Lexicon Pharmaceuticals Inc, Common Stock

LXRX

NSQ

$0.7147

-$0.01

(-1.38%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$244.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
6.93M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.24
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.62 L
$3.73 H
$0.7147

About Lexicon Pharmaceuticals Inc, Common Stock

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLXRXSectorS&P500
1-Week Return-11.8%-2.12%-3%
1-Month Return-11.48%-3.42%-0.73%
3-Month Return-56.95%-11.13%2.87%
6-Month Return-59.16%-5.74%7.17%
1-Year Return-41.42%3.97%25.31%
3-Year Return-81.72%1.05%28.38%
5-Year Return-83.79%34.37%81.89%
10-Year Return-88.7%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue322.07M24.00M298.00K139.00K1.20M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":7.45,"profit":true},{"date":"2021-12-31","value":0.09,"profit":true},{"date":"2022-12-31","value":0.04,"profit":true},{"date":"2023-12-31","value":0.37,"profit":true}]
Cost of Revenue3.23M1.93M55.05M427.00K85.00K[{"date":"2019-12-31","value":5.87,"profit":true},{"date":"2020-12-31","value":3.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.78,"profit":true},{"date":"2023-12-31","value":0.15,"profit":true}]
Gross Profit318.84M22.07M(54.75M)(288.00K)1.12M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":6.92,"profit":true},{"date":"2021-12-31","value":-17.17,"profit":false},{"date":"2022-12-31","value":-0.09,"profit":false},{"date":"2023-12-31","value":0.35,"profit":true}]
Gross Margin99.00%91.96%(18371.81%)(207.19%)92.94%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.89,"profit":true},{"date":"2021-12-31","value":-18557.98,"profit":false},{"date":"2022-12-31","value":-209.29,"profit":false},{"date":"2023-12-31","value":93.88,"profit":true}]
Operating Expenses148.76M200.85M87.39M100.90M172.87M[{"date":"2019-12-31","value":74.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.51,"profit":true},{"date":"2022-12-31","value":50.24,"profit":true},{"date":"2023-12-31","value":86.07,"profit":true}]
Operating Income141.44M(178.78M)(87.09M)(100.76M)(171.75M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-126.4,"profit":false},{"date":"2021-12-31","value":-61.57,"profit":false},{"date":"2022-12-31","value":-71.24,"profit":false},{"date":"2023-12-31","value":-121.43,"profit":false}]
Total Non-Operating Income/Expense(34.65M)(22.55M)(1.34M)(2.37M)(7.93M)[{"date":"2019-12-31","value":-3465200000,"profit":false},{"date":"2020-12-31","value":-2255100000,"profit":false},{"date":"2021-12-31","value":-133600000,"profit":false},{"date":"2022-12-31","value":-236800000,"profit":false},{"date":"2023-12-31","value":-793500000,"profit":false}]
Pre-Tax Income124.12M(58.57M)(87.76M)(101.94M)(177.12M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-47.19,"profit":false},{"date":"2021-12-31","value":-70.7,"profit":false},{"date":"2022-12-31","value":-82.13,"profit":false},{"date":"2023-12-31","value":-142.7,"profit":false}]
Income Taxes(6.01M)11.61M510.00K1.18M386.11K[{"date":"2019-12-31","value":-51.8,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":4.39,"profit":true},{"date":"2022-12-31","value":10.2,"profit":true},{"date":"2023-12-31","value":3.33,"profit":true}]
Income After Taxes130.13M(70.18M)(88.27M)(103.13M)(177.51M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-53.93,"profit":false},{"date":"2021-12-31","value":-67.83,"profit":false},{"date":"2022-12-31","value":-79.25,"profit":false},{"date":"2023-12-31","value":-136.4,"profit":false}]
Income From Continuous Operations130.13M(58.57M)(87.76M)(101.94M)(157.86M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-45.01,"profit":false},{"date":"2021-12-31","value":-67.44,"profit":false},{"date":"2022-12-31","value":-78.34,"profit":false},{"date":"2023-12-31","value":-121.3,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income130.13M(70.18M)(88.27M)(103.13M)(177.12M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-53.93,"profit":false},{"date":"2021-12-31","value":-67.83,"profit":false},{"date":"2022-12-31","value":-79.25,"profit":false},{"date":"2023-12-31","value":-136.11,"profit":false}]
EPS (Diluted)1.20(0.60)(0.61)(0.61)(0.80)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-50,"profit":false},{"date":"2021-12-31","value":-50.83,"profit":false},{"date":"2022-12-31","value":-50.83,"profit":false},{"date":"2023-12-31","value":-66.67,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LXRX
Cash Ratio 7.17
Current Ratio 7.45
Quick Ratio 7.43

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LXRX
ROA (LTM) -44.16%
ROE (LTM) -136.09%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LXRX
Debt Ratio Lower is generally better. Negative is bad. 0.44
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.56

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LXRX
Trailing PE NM
Forward PE NM
P/S (TTM) 50.02
P/B 1.45
Price/FCF NM
EV/R 19.35
EV/Ebitda NM
PEG NM

FAQs

What is Lexicon Pharmaceuticals Inc share price today?

Lexicon Pharmaceuticals Inc (LXRX) share price today is $0.7147

Can Indians buy Lexicon Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Lexicon Pharmaceuticals Inc (LXRX) on Vested. To buy Lexicon Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LXRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lexicon Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Lexicon Pharmaceuticals Inc (LXRX) via the Vested app. You can start investing in Lexicon Pharmaceuticals Inc (LXRX) with a minimum investment of $1.

How to invest in Lexicon Pharmaceuticals Inc shares from India?

You can invest in shares of Lexicon Pharmaceuticals Inc (LXRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in LXRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lexicon Pharmaceuticals Inc shares
What is Lexicon Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Lexicon Pharmaceuticals Inc (LXRX) is $3.73. The 52-week low price of Lexicon Pharmaceuticals Inc (LXRX) is $0.62.

What is Lexicon Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Lexicon Pharmaceuticals Inc (LXRX) is

What is Lexicon Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lexicon Pharmaceuticals Inc (LXRX) is 1.45

What is Lexicon Pharmaceuticals Inc dividend yield?

The dividend yield of Lexicon Pharmaceuticals Inc (LXRX) is 0.00%

What is the Market Cap of Lexicon Pharmaceuticals Inc?

The market capitalization of Lexicon Pharmaceuticals Inc (LXRX) is $244.80M

What is Lexicon Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Lexicon Pharmaceuticals Inc is LXRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top